Novocure.com
TTFields
Tumor Treating Fields (TTFields) are electric fields that disrupt cancer cell division. TTFields are delivered to the region of the cancer using a lightweight, battery-operated medical device. Novocure is the sponsor of several clinical studies investigating TTFields treatment for different types of cancer.
Using TTFields
TTFields are delivered to the region of the tumor using a lightweight, portable medical device. The device applies TTFields non-invasively and gives patients the option to maintain their lifestyle while receiving TTFields treatment.
Novocure
Novocure is developing TTFields for different cancer diseases. Novocure maintains this website in order to assist patients, their family members, and caregivers in accessing clinical study sites for potential participation in ongoing trials. Patients should always consult with their treating physician about their treatment options.
Novocure Trials – Cancer Clinical Trials
Overview
Novocure® is developing TTFields for different cancer diseases. This website is designed to assist patients, their family members, and caregivers in accessing clinical study sites for potential participation in ongoing studies.
TTFields are electric fields that disrupt cancer cell division. TTFields are delivered to the region of the cancer using a lightweight, battery-operated medical device. The device applies TTFields non-invasively, and gives patients the option to maintain their lifestyle while receiving TTFields treatment.
The use of TTFields has been approved by the FDA via the Premarket Approval Pathway for the treatment of GBM, together with temozolomide. TTFields therapy has obtained a CE mark in Europe, and is approved in Japan for the same indication. TTFields are experimental for all indications mentioned in these clinical studies and has not been approved for their treatment.
clinical trials
METIS
Brain metastasis
The METIS study is intended for patients diagnosed with brain metastases from non-small-cell lung cancer.
learn more
LUNAR
Lung cancer
The LUNAR study is intended for patients diagnosed with advanced non-small cell lung cancer (NSCLC).
learn more
ENGOT-ov50 / INNOVATE-3
Ovarian cancer
The ENGOT-0v50/INNOVATE-3 study is intended for patients diagnosed with platinum resistant, recurrent ovarian cancer.
learn more
TRIDENT
Glioblastoma
The TRIDENT study is intended for patients recently diagnosed with glioblastoma multiforme (GBM).
learn more
ZL-8301-001
Gastric cancer
The ZL-8301-001 study is intended for patients diagnosed with gastric cancer (Gastroesophageal Junction (GEJ) Adenocarcinoma, or Gastric (GC) Adenocarcinoma) that cannot be treated with surgery.
learn more
PANOVA-3
Pancreatic cancer
The PANOVA-3 study is intended for patients with newly-diagnosed pancreatic cancer that cannot be treated with surgery.
learn more
EF-33
Glioblastoma
The EF-33 study is intended for patients recently diagnosed with recurrent glioblastoma.
learn more
KEYNOTE B36
Lung cancer
A pilot, randomized, open-label study of Tumor Treating Fields (TTFields, 150 kHz) concomitant with pembrolizumab for first line treatment of advanced or metastatic non-small cell lung cancer.
learn more
Find Cancer Clinical Trials
The best way to learn more about eligibility for one of our trials is to contact a study center near you. To filter study results by condition or trial: fill in the fields below, enter your location, and click “find trials”. Click the trial icon to visit the study page, and learn more about that trial.